These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 23196937)
1. Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy. Lacombe JM; Boue F; Grabar S; Viget N; Gazaignes S; Lascaux-Cametz AS; Pacanowski J; Partisani M; Launay O; Matheron S; Rosenthal E; Rouveix E; Tattevin P; de Truchis P; Costagliola D; Goedert JJ AIDS; 2013 Feb; 27(4):635-43. PubMed ID: 23196937 [TBL] [Abstract][Full Text] [Related]
2. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. Lodi S; Guiguet M; Costagliola D; Fisher M; de Luca A; Porter K; J Natl Cancer Inst; 2010 Jun; 102(11):784-92. PubMed ID: 20442214 [TBL] [Abstract][Full Text] [Related]
3. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Lodi S; van Sighem A; de Wolf W; Sabin C; Bansi L; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Toulomi G; Gargalianos P; Costagliola D; Abgrall S; Hernán MA; Clin Infect Dis; 2012 May; 54(9):1364-72. PubMed ID: 22460971 [TBL] [Abstract][Full Text] [Related]
4. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. Jaffe HW; De Stavola BL; Carpenter LM; Porter K; Cox DR; AIDS; 2011 Jul; 25(11):1395-403. PubMed ID: 21572307 [TBL] [Abstract][Full Text] [Related]
5. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Guiguet M; Boué F; Cadranel J; Lang JM; Rosenthal E; Costagliola D; Lancet Oncol; 2009 Dec; 10(12):1152-9. PubMed ID: 19818686 [TBL] [Abstract][Full Text] [Related]
6. Predictors of immune reconstitution inflammatory syndrome-associated with kaposi sarcoma in mozambique: a prospective study. Letang E; Almeida JM; Miró JM; Ayala E; White IE; Carrilho C; Bastos R; Nhampossa T; Menéndez C; Campbell TB; Alonso PL; Naniche D J Acquir Immune Defic Syndr; 2010 Apr; 53(5):589-97. PubMed ID: 19801945 [TBL] [Abstract][Full Text] [Related]
7. Kaposi sarcoma in people living with HIV: incidence and associated factors in a French cohort between 2010 and 2015. Poizot-Martin I; Lions C; Cheret A; Rey D; Duvivier C; Jacomet C; Allavena C; Huleux T; Bani-Sadr F; Obry-Roguet V; Makinson A; AIDS; 2020 Mar; 34(4):569-577. PubMed ID: 31764070 [TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma. Volkow P; Cesarman-Maus G; Garciadiego-Fossas P; Rojas-Marin E; Cornejo-Juárez P AIDS Res Ther; 2017 May; 14(1):30. PubMed ID: 28558783 [TBL] [Abstract][Full Text] [Related]
9. Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies. Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord Clin Infect Dis; 2016 Nov; 63(10):1373-1379. PubMed ID: 27535953 [TBL] [Abstract][Full Text] [Related]
10. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL. Atkinson A; Miro JM; Mocroft A; Reiss P; Kirk O; Morlat P; Ghosn J; Stephan C; Mussini C; Antoniadou A; Doerholt K; Girardi E; De Wit S; Kraus D; Zwahlen M; Furrer H; J Int AIDS Soc; 2021 Jun; 24(6):e25726. PubMed ID: 34118121 [TBL] [Abstract][Full Text] [Related]
11. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862 [TBL] [Abstract][Full Text] [Related]
12. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. Letang E; Lewis JJ; Bower M; Mosam A; Borok M; Campbell TB; Naniche D; Newsom-Davis T; Shaik F; Fiorillo S; Miro JM; Schellenberg D; Easterbrook PJ AIDS; 2013 Jun; 27(10):1603-13. PubMed ID: 23462220 [TBL] [Abstract][Full Text] [Related]
13. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort. Grabar S; Tattevin P; Selinger-Leneman H; de La Blanchardiere A; de Truchis P; Rabaud C; Rey D; Daneluzzi V; Ferret S; Lascaux AS; Hanslik T; Costagliola D; Launay O; Clin Infect Dis; 2015 Apr; 60(8):1269-77. PubMed ID: 25601456 [TBL] [Abstract][Full Text] [Related]
14. Use of boosted protease inhibitors reduces Kaposi sarcoma incidence among male veterans with HIV infection. Kowalkowski MA; Kramer JR; Richardson PR; Suteria I; Chiao EY Clin Infect Dis; 2015 May; 60(9):1405-14. PubMed ID: 25586682 [TBL] [Abstract][Full Text] [Related]
15. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Lanoy E; Rosenberg PS; Fily F; Lascaux AS; Martinez V; Partisani M; Poizot-Martin I; Rouveix E; Engels EA; Costagliola D; Goedert JJ; Blood; 2011 Jul; 118(1):44-9. PubMed ID: 21551234 [TBL] [Abstract][Full Text] [Related]
16. Early development of immune reconstitution inflammatory syndrome related to Pneumocystis pneumonia after antiretroviral therapy. Mok HP; Hart E; Venkatesan P Int J STD AIDS; 2014 Apr; 25(5):373-7. PubMed ID: 24122663 [TBL] [Abstract][Full Text] [Related]
17. Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. ; Rohner E; Schmidlin K; Zwahlen M; Chakraborty R; Clifford G; Obel N; Grabar S; Verbon A; Noguera-Julian A; Collins IJ; Rojo P; Brockmeyer N; Campbell M; Chêne G; Prozesky H; Eley B; Stefan DC; Davidson A; Chimbetete C; Sawry S; Davies MA; Kariminia A; Vibol U; Sohn A; Egger M; Bohlius J Clin Infect Dis; 2016 Nov; 63(9):1245-1253. PubMed ID: 27578823 [TBL] [Abstract][Full Text] [Related]
18. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991. Muñoz A; Schrager LK; Bacellar H; Speizer I; Vermund SH; Detels R; Saah AJ; Kingsley LA; Seminara D; Phair JP Am J Epidemiol; 1993 Feb; 137(4):423-38. PubMed ID: 8096356 [TBL] [Abstract][Full Text] [Related]
19. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. Ledergerber B; Egger M; Erard V; Weber R; Hirschel B; Furrer H; Battegay M; Vernazza P; Bernasconi E; Opravil M; Kaufmann D; Sudre P; Francioli P; Telenti A JAMA; 1999 Dec; 282(23):2220-6. PubMed ID: 10605973 [TBL] [Abstract][Full Text] [Related]